The expression of the ANXA10 protein is observed in about 45% (42–49%) of sporadic CRC, irrespective of the presence of a BRAF mutation, but in a low proportion of LS-related CRC (5–12%), suggesting that ANXA10 immunohistochemistry may be used as a supportive marker in association with BRAF to distinguish LS and sporadic MSI/dMMR CRC [291,292]. This evidence concerns the gene BRAF and colorectal carcinoma.